Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2005
12/08/2005WO2005115360A2 Formulations of anti-pain agents and methods of using the same
12/08/2005WO2005115355A1 Pasting preparation
12/08/2005WO2005115353A1 Pharmaceutical suspension composition
12/08/2005WO2005115339A2 Composition for enhancing absorption of a drug and method
12/08/2005WO2005115335A1 Spot-on formulation useful for cosmetology and dermatology
12/08/2005WO2005115333A2 A biomolecule-containing formulation of increased stability
12/08/2005WO2005115173A1 Medicinal products incorporating bound organosulfur groups
12/08/2005WO2005115105A2 Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase
12/08/2005WO2005105148A8 Liquid growth hormone formulation
12/08/2005WO2005104648A3 Pegylated nanoparticles
12/08/2005WO2005101982A3 A stable ophthalmic composition
12/08/2005WO2005099713A3 Novel antiviral pharmaceutical composition
12/08/2005WO2005097073A8 Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases
12/08/2005WO2005082428A3 Plaster that reduces skin irritation
12/08/2005WO2005079852A3 Bacteriostatic esters for topical use
12/08/2005WO2005042142A8 Thermosensitive, biocompatible polymer carriers with a variable physical structure for treatment, diagnosis and analysis
12/08/2005WO2005041882A3 Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
12/08/2005WO2005034997A3 Conjugate of a photosensitiser and a bacteriophage
12/08/2005WO2005034909A3 Hyperbranched polymer conjugates via non-enzymatic cleavable linker
12/08/2005WO2005027977A3 Diclofenac compositions for the treatment of skin disorders
12/08/2005WO2004100935A3 Propofol formulation containing reduced oil and surfactants
12/08/2005WO2003065982A3 Engineering absorption of therapeutic compounds via colonic transporters
12/08/2005US20050272922 Processes for preparing crosslinker-free, biopolymer-containing three dimensional structures, and products prepared thereby
12/08/2005US20050272822 Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
12/08/2005US20050272815 Compounds and compositions for delivering active agents
12/08/2005US20050272806 Injectable formulations of taxanes for cad treatment
12/08/2005US20050272798 Analogues of rachelmycin and the duocarmycins that are potent cytotoxins containing a benzodipyrrole or naphthopyrrole ring; anticancer agents
12/08/2005US20050272729 Cytotoxic agents comprising taxanes and their therapeutic use
12/08/2005US20050272714 Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity
12/08/2005US20050272710 Providing sustained systemic concentrations of therapeutic or prophylactic agents such as gamma-aminobutyric acid derivatives following oral adiminstration to animals
12/08/2005US20050272701 Pharmaceutical composition
12/08/2005US20050272677 Delivery of a substance to a pre-determined site
12/08/2005US20050272670 Synthesis and use of glycodendrimer reagents
12/08/2005US20050272662 Self-assembled peptide-amphiphiles & self-assembled peptide nanofiber networks presenting multiple signals
12/08/2005US20050272657 Human growth hormone aqueous formulation
12/08/2005US20050272639 Crystalline polymorph of the pentahydrate form in synergistic combination with another active ingredient to enhance drug delivery; antidiabetic agents
12/08/2005US20050272638 Improved bioavailability; for oral and intracolonic administration
12/08/2005US20050272626 Alkoxylates exhibiting low residual alcohol content
12/08/2005US20050272161 Fixed-dried red blood cells or blood platelets carrying an active agent which, upon reconstitution, adhere to thrombogenic surfaces, undergo shape change, form a hemostatic plug, and release their granular contents
12/08/2005US20050271758 Topical compositions containing Bacillus coagulans extracellular products and uses thereof
12/08/2005US20050271748 Compositions for treating hyperemia
12/08/2005US20050271745 Magnetic nanoparticle compositions, and methods related thereto
12/08/2005US20050271743 Treatment of inflammatory skin conditions
12/08/2005US20050271729 Via 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide methiodide; freeze drying
12/08/2005US20050271728 High molecular weight medicine-containing preparation in powder form for administration through mucosa
12/08/2005US20050271726 Immune enhancing compositions and methods of use thereof
12/08/2005US20050271725 Adhesive gel composition for iontophoresis preparation and process for producing the same
12/08/2005US20050271722 complex composed of a protein and/or peptide and a gallic acid ester that allow for sustained delivery of the protein or peptide in vivo upon administration of the complex; gallic acid ester is epigallocatechin gallate
12/08/2005US20050271721 Carvedilol-hydrophilic solutions
12/08/2005US20050271716 Preparation containing basic drug
12/08/2005US20050271715 Conjugate having a cleavable linkage for use in a liposome
12/08/2005US20050271714 a cationic lipid; and a taxane in a lipid bilayer of the taxane crystal free liposome
12/08/2005US20050271713 Topical anesthetic preparation for pretreatment for upper gastrointestinal endoscopy
12/08/2005US20050271711 Therapeutic antimicrobial compositions and methods
12/08/2005US20050271702 polyglycolic acid or polylactic acid or glycolic acid-lactic acid copolymer as biocompatible polymer having dispersed therein about 3%-5% (w/w) exendin-4 and about 2% (w/w) sucrose; antidiabetic agent
12/08/2005US20050271699 Biodegradable composition with prolonged release of the biological active compound and preparation thereof
12/08/2005US20050271696 Medical device having a surface including a biologically active agent therein, and methods
12/08/2005US20050271679 Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
12/08/2005US20050271673 Trifunctional reagent for conjugation to a biomolecule
12/08/2005US20050271672 Maytansinoids; use in cancer tumor therapy
12/08/2005US20050271671 Anthracycline-antibody conjugates
12/08/2005US20050271663 treating rheumatoid arthritis by using single domain antibody polypeptide construct that binds human TNF- alpha
12/08/2005US20050271653 Methods and devices for targeting a site in a mammal and for removing species from a mammal
12/08/2005US20050271631 Material compositions and related systems and methods for treating cardiac conditions
12/08/2005US20050271620 Herpes simplex virus complex
12/08/2005US20050271618 Methods of reducing aggregation of IL-1ra
12/08/2005US20050271615 Self-immolative dendrimers releasing many active moieties upon a single activating event
12/08/2005US20050271588 Liposome targeting of matrix metalloproteinase inhibitors
12/08/2005US20050271571 Hydroxapatite calcium phosphates, their method of preparation and their applications
12/08/2005US20050269722 Process for the preparation of pharmaceutical microcapsules with enhanced taste-masking and high dissolution rate
12/08/2005US20050269546 Valve with a two-component seal
12/08/2005DE102004023069A1 Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil New dosage forms of the PDE 5 inhibitor vardenafil
12/08/2005DE102004022928A1 Pulver enthaltend neuartige Oligosacharidgemische und Verfahren zu deren Herstellung Powder containing Oligosacharidgemische novel and processes for their preparation
12/08/2005CA2568714A1 A biomolecule-containing formulation of increased stability
12/08/2005CA2568409A1 A chronic joint inflammation-modulating composition made of collagen-polyvinylpyrrolidone
12/08/2005CA2568363A1 Natriuretic compounds, conjugates, and uses thereof
12/08/2005CA2567075A1 Pharmaceutical suspension composition
12/08/2005CA2567056A1 Compositions and methods for enhanced mucosal delivery of parathyroid hormone
12/08/2005CA2566481A1 Peptides or peptidic conjugate derivatives of msh and the use thereof for cosmetically fighting against canities
12/08/2005CA2565805A1 Msh-agonist tripeptide conjugates
12/08/2005CA2565556A1 Polycationic antimicrobial therapeutic
12/08/2005CA2562565A1 Spot-on formulation useful for cosmetology and dermatology
12/07/2005EP1602667A1 Aqueous formulation comprising TFPI and solubilising agents
12/07/2005EP1602656A1 Pyrazole derivatives having affinity for cb1 and/or cb2 receptors
12/07/2005EP1602367A1 Transdermal delivery system for treatment of cognitive disorders
12/07/2005EP1602366A1 Patch material for ionic medicine administration
12/07/2005EP1602361A2 Antibiotic in the form of a water-soluble powder for veterinary and human use
12/07/2005EP1602360A1 Method of obtaining cochlear structures, vaccine compositions, adjuvants and intermediates thereof
12/07/2005EP1601721A1 Biodegradable polyacetals
12/07/2005EP1601698A1 Physiologically active polypeptide conjugate having prolonged in vivo half-life
12/07/2005EP1601661A2 Compositions and methods for preventing and treating endotoxin-related diseases and conditions
12/07/2005EP1601381A2 Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
12/07/2005EP1601373A2 Intracellular delivery of small molecules proteins and nucleic acids
12/07/2005EP1601359A1 Liquid pharmaceutical formulations of palonosetron
12/07/2005EP1601330A2 Antitumor agents comprising a targeting portion and an immune response triggering portion
12/07/2005EP1601326A2 Random alkylene oxide copolymers for medical and surgical utilities
12/07/2005EP1583561A3 Tissue reactive compounds and compositions and uses thereof
12/07/2005EP1485500A4 Efficient synthesis of protein-oligonucleotide conjugates
12/07/2005EP1463408A4 Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin
12/07/2005EP1425381A4 Emu-based formulations for wound treatment related application information
1 ... 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 ... 1712